Testing effectiveness (Phase 2)Looking for participantsNCT07165769
What this trial is testing
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
Who this might be right for
Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli,SBLPN
Institute of Hematology & Blood Diseases Hospital, China 47